Loading data for INDV — first visit, this takes a few seconds.
Indivior Pharmaceuticals, Inc.
34.47 -0.02 (-0.06%)
- Ринкова капіталізація
- $4.07B
- Обсяг торгів
- 1.72M
- Наступна дата звітності
- Nov 5, 2026
Indivior Pharmaceuticals, Inc. (INDV): ціна акції, аналіз і дані
Внутрішня вартість
Прогноз аналітиків
Прогнози по акціях →Останні результати
| Факт | До прогнозу | Зміна р/р | |
|---|---|---|---|
| Виручка | $343.0M | n/a | +13.58% |
| EPS | $1,15 | +$0,23 | +125.49% |
Показники
- Купівля
- 34.74
- Ринкова капіталізація
- 4.07B
- Виручка (ttm)
- 1.33B
- Чистий прибуток (ttm)
- 356M
- 1.11
- 2.79
- 12.35
- 7.06
- P/B (ttm)
- -19.55
- P/S (ttm)
- 3.06
- Дата звіту
- Nov 5, 2026
- Продаж
- 34.74
- Обсяг торгів
- 1,719,775
- Сер. обсяг (20 дн.)
- 2,046,680
- Відкриття
- 34.74
- Попереднє закриття
- 34.49
- Діапазон дня
- 34.15 - 35.01
- Діапазон за 52 тижні
- 22.22 - 42.81
- Аналітик
- n/a
- Цільова ціна
- n/a
- Дивіденди
- n/a
- Екс-дивідендна дата
- Jun 16, 2016
Про Indivior Pharmaceuticals, Inc.
Профіль →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.